Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]
News & EventsNews & Events
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational TherapyDesigned to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma -Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application- Wellesley, Mass., April 15, 2021 — Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic […]